Appointment of Nominated Adviser and Joint Broker

RNS Number : 7572O

Advanced Oncotherapy PLC

01 February 2019

 

1 February 2019

ADVANCED ONCOTHERAPY PLC

("Advanced Oncotherapy" or the "Company")

Appointment of Nominated Adviser and Joint Broker

Advanced Oncotherapy (AIM: AVO), the developer of a next-generation proton therapy system for cancer treatment, is pleased to announce the appointment of Allenby Capital Limited as the Company's nominated adviser and joint broker with immediate effect.

For further information, please contact:

Advanced Oncotherapy Plc	Tel: [phone]
Dr. Michael Sinclair, Executive Chairman	www.avoplc.com
Nicolas Serandour, CEO
Allenby Capital Limited  (Nominated Adviser & Joint Broker)	Tel: [phone]
Nick Athanas / Liz Kirchner / Nicholas Chambers
Stifel Nicolaus Europe (Joint Broker)	Tel: [phone]
Jonathan Senior
Walbrook PR (Financial PR & IR) Paul McManus / Anna Dunphy	Tel: [phone] [e-mail]
	Mob: [phone] Mob: [phone]

About Advanced Oncotherapy Plc

Advanced Oncotherapy is a provider of particle therapy in the treatment of cancer, which harnesses the very best in modern technology. Advanced Oncotherapy's R&D team, ADAM, in Geneva, focuses on the development of a proprietary proton accelerator - LIGHT (Linac Image Guided Hadron Technology). LIGHT accelerates protons to the energy levels achieved in legacy machines but in a compact and truly modular unit, offering significant cost advantages. LIGHT also delivers proton beams in a way that facilitates greater precision and electronic control, which are not achievable with currently available alternative technologies.

Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with an innovative technology, offering better health outcomes and lower treatment related side effects.

Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton or particle therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of cutting edge, cost-effective systems for particle therapy.

 

END

 

 

APPEAPFFDLANEFF